Angiotensin-converting enzyme inhibitors: Congestive heart failure and beyond

Coronary Artery Disease

Volumn 10, Issue 6, 1999, Pages 361-368

  Lombardi, William L ^a   Litwin, Sheldon E ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitor; Heart failure; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; QUINAPRIL; RAMIPRIL; ZOFENOPRIL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLE; DRUG COST; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEX DIFFERENCE;

EID: 0032872357     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199909000-00003     Document Type: Review

References (69)

1. Struthers Allen D. The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. Pharmac Ther 1992; 53:187-197.
2. Raya TE, Gay RG, Aquirre M, Goldman S. Importance of venodilation in prevention of left ventricular dilation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res 1989; 64:330-337.
3. Weinberg EO, Lee MA, Weigner M, Lindpainter K, Bishop SP. Benedict CR, et al. Angiotensin AT, receptor inhibition: effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation 1997; 95:1592-1600.
4. Linz W, Schollrens BA, Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens 1991; 9 (suppl):S400-S401.
5. Zimmerman BG. Actions of angiotensin on adrenergic nerve findings. Fed Proc 1978; 37:199-202.
6. Seidelin PH, Benjamin N, Collier JG, Struthers AD, Webb DJ, Intra-arterial angiotensin II augments sympathetically mediated vasoconstriction in forearm resistance vessels in man. Clin Sci 1991; 81:261-266.
7. Yusuf S, Thom T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989; 13:174-179.
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435. Two-hundred and fifty-three patients with NYHA class IV heart failure symptoms were randomly assigned in a double-blind fashion to enalapril (2.5-40 mg/day) or placebo. Addition of enalapril to conventional therapy in patients with severe CHF can reduce mortality and improve symptoms.
9. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Ristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310. Eight-hundred and four men receiving digoxin and diuretic therapy for heart failure were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate. Enalapril produced a significant difference in mortality compared with hydralazine/isosorbide (18% versus 25% 2-year mortality, respectively).
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302. Patients receiving conventional treatment for heart failure were randomly assigned to either placebo (n = 1284) or enalapril (n = 1285) at doses of 2.5-20 mg/day and then followed for an average of 41.4 months. The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic CHF and low ejection fractions.
11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327:685-691. Asymptomatic patients with ejection fractions less than 35% were randomly assigned to receive either placebo (n = 2117) or enalapril (n = 2111) at doses of 2.5-20 mg/day and were followed for 37.4 months on average. Enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, compared with the rates in the group receiving placebo.
12. Northridgo DN, Rose E, Raftery ED, Lahiri A, Elder AT, Shaw TRD, et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. Eur Heart J 1993; 14:403-409.
13. Giles TD, Katz R, Sullivan JM, Wolfson P. Haugland M, Kirlin P. et al. Short-and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989; 13:1240-1247.
14. Colfer HT, Ribner HS, Gradman A, Hughs V, Kapoor A, Laidlaw JC, for the Benazepril Heart Failure Study Group. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am J Cardiol 1992; 70:354-358.
15. Brown EJ. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol 1995; 75:596-600.
16. Colfer HT, Ribner HS, Gradman A, Hughes CV, Kapoor A, Laidlaw JC, et al. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am J Cardiol 1992; 70:354-358.
17. Rieggor GAJ. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1990; 15 (suppl 2):S41-S46.
18. Lewis GR. Comparison of lisinopril versus placebo for congestive heart failure. Am J Cardiol 1989; 63:12D-16D.
19. Boschetti E, Tantucci CL, Coccieri M, Castellano M, Alumni G, Bruni B, et al. Sympathetic activation on effort in patients with chronic heart failure: long term effects of captoprll. Acta Cardiol 1988; 43:569-582.
20. Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 1984; 70:271-278.
21. Franciesco P, Borghi A, Ruggieri A, Cianfrocca C, Morgagni GL, Bugiardini R. Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure. Clin Cardiol 1993; 16:607-612.
22. Packer M. Why do the kidneys release rennin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol 1987; 60:179-184.
23. Rfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677. Patients with ejection fractions less than 40% without overt heart failure or symptoms of myocardial ischemia (n = 2231 ) were randomly assigned to placebo or captopril in a double blind fashion 3-16 days after myocardial infarction. In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduced morbidity and mortality from major cardiovascular events.
24. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-1122. This multicenter, randomized clinical trial of 19 394 patients was designed to assess the efficacy of lisinopril, transdermal glyceryl trinitrate, and their combination (over a 6-week treatment period) in improving survival and ventricular function after acute myocardial infarction. Treatment with lisinopril within 24 h of acute myocardial infarction produced significant reductions in overall mortality and in the combined outcome measure of mortality and severe ventricular dysfunction.
25. Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the hemodynamic and clinical response to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol 1984; 3:1035-1043.
26. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with heart failure. Arch Intern Med 1995; 154:1143-1149.
27. Fedelson JT, Weinstein MC, Tosteson ANA, Williams L, Lee TH, Goldman L. Long-term cost effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263:407-413.
28. Stange PV, Sumner AT, Predicting treatment costs and life expectancy for end stage renal disease. N Engl J Med 1978; 298:372-378.
29. Kupersmith J, Forrester JS. Cost effectiveness analysis applications: AJCD. American College of Cardiology Extended Learning tape, Vol. 29(10), Tape A, side two, October 1997.
30. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450-1456.
31. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observation and clinical implications. Circulation 1990; 81:1161-1172.
32. McKelvie R, McConachie D, Yusuf S. Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure. Eur Heart J 1994; 15 (suppl B):9-13.
33. Erlebacher JA, Richter RC, Alonso DR, Devereux RB, Gay WA Jr. Early infarct expansion. Structural or functional? J Am Coll Cardiol 1985; 6:839-844.
34. Swedberg K, Held P. Kjekshus J, Rasmussen K, Ryden L, Wedel H, on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327:678-684. In this study, intravenous enalapril was given within 24 h of the onset of chest pain, followed by administration of oral enalapril in a randomized fashion to 6090 patients. Enalapril therapy started within 24 h of the onset of acute myocardial infarction did not improve survival during the 180 days after infarction.
35. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685. In this study 58 050 patients were treated for 4 weeks after acute myocardial infarction with captopril (6.25 mg initially titrated to 50 mg twice daily) versus placebo. There was a significant reduction in 5-week mortaity which persisted for the long-term, and in those patients with previous myocardial infarction or heart failure the benefit seemed to be greater.
36. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332:80-85.
37. Kingma JH, van Gilst WH, Peels CH, Dambrink J-HE, Verheugt FWA, Wielenga RP, for the CATS investigators. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril And Thrombolysis Study (CATS). Eur Heart J 1994; 15:898-907.
38. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. Effects on mortality by trandolapril after myocardial infarction. N Engl J Med 1995; 333:1670-1676.
39. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828.
40. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Daganais GR, et al. for the SAVE investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation 1994; 89:68-75.
41. Bonaduce D, Petretta M, Arrichiello P, Confori G, Montemurro MV, Attisano T, et al. Effects of captopril treatment on left ventricular remodeling and function after anterior myocardial infarction: comparison with digitalis. J Am Coll Cardiol 1992; 19:858-863.
42. Doherty NE, Seelos KC, Suzuki J, Caputo GR, O'Sullivan M, Sobol SM, et al. Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy. J Am Coll Cardiol 1992; 19:1294-1302.
43. Litwin SE, Katz SE, Morgan JP, Douglas PS. Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction. J Am Coll Cardiol 1996; 28:773-781.
44. Friedrich SP, Lorell BH, Rousseau MF, Hayashida W, Hess OM, Douglas PS, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994; 90:2761-2671.
45. Gheorghiade M, Bonow RO. Chronic heart failure in the United States, a manifestation of coronary artery disease. Circulation 1998; 97:282-289.
46. Cannon PJ. Prostaglandins in congestive heart failure and the effects of nonsteroidal antiinflammatory drugs. Am J Med 1986; 81 (suppl 28):123-131.
47. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. N Engl J Med 1984; 310:347-352.
48. Nishimura H, Kubo S, Ueyama M, Kubota J, Kawamura K. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J 1989; 117:100-105.
49. Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol 1993; 22 (suppl A):158A-161A.
50. Cleland JGF. ACE inhibitors for myocardial infarction: how should they be used? Eur Heart J 1995; 16:153-159.
51. Nguyen KN, Aursnes I, Snappin S, Kjekshus J. Antagonism between enalapril and aspirin: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) [abstract]. J Am Coll Cardiol 1995; 25 (suppl A):23A.
52. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979; ii:1313-1315.
53. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974; i:436-440.
54. The Persantine-Aspirin Reinfarction Study (PARIS) Research group. Persantine and aspirin in coronary heart disease. Circulation 1980; 62:449-462.
55. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-269.
56. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243:661-668.
57. Cleland JGF, Poole-Wilson PA. ACE inhibitors for heart failure: a question of dose. Br Heart J 1994; 72 (suppl):S106-S145.
58. Cleland JGF. The clinical course of heart failure and its modification by ACE inhibitors: Insights from recent clinical trails. Eur Heart J 1994; 15:125-130.
59. Fisher LD, Kennedy JW, Davis KB, Maynard C, Fritz JK, Kaiser GC, et al. and the participating CASS clinics. Association of sex, physical size and operative mortality after coronary artery bypass in the Coronary Artery Surgery Study (CASS). J Thorac Cardiovasc Surg 1982; 84:334-341.
60. Kennedy JW, Kaiser GC, Fisher LD, Fritz JK, Myers W, Mudd G, et al. Clinical and angiographic predictors of operative mortality from the Collaborative Study in Coronary Artery Surgery (CASS). Circulation 1981; 63:793-802.
61. Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre KM, and Investigators from the National Heart, Lung, and Blood Institute Percutaneous Coronary Angioplasty Registry. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993;87:720-727.
62. Jacobs AK, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98:1279-1285.
63. Conn JN, Archibald DG, Ziesche S, Franchiosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552.
64. The MDC Trial study group. Metoprolol in dilated cardiomyopathy: multicenter randomized placebo-controlled trial [abstract]. Circulation 1992; 86 (suppl):l118.
65. Kimmelstiet CD, Goldberg RJ. Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. Cardiology 1990; 77 (suppl 2):71-79.
66. Limacher MC, Ysuf S, for the SOLVD Investigators. Gender differences in presentation, morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD): a preliminary report. In: Wenger JK, Speroff L, Packard B (editors): Cardiovascular disease in women. Greenwich, CT: Le Jacq Communications, Inc.; 1993. pp. 345-348
67. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Blekin RN, et al. Effect of amilodipine on morbidity and mortality in severe heart failure. N Engl J Med 1996; 335:1107-1114.
68. Cohn J, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al., for the Vasodilator-Heart-Failure Trial (V-HeFT) Study Group. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. Circulation 1997; 96:856-863.
69. Vantrimpont P, Rouleu JL, Wun CC, Ciampi A, Klein M, Sussex B, et al., for the SAVE investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement(SAVE) study. J Am Coll Cardiol 1997; 29:229-236.